Welcure Drugs & Pharmaceuticals Ltd has announced plans for establishing a dedicated Agro-Pharma Research Laboratory with an estimated investment of ₹70-80 crore, alongside a proposed ₹80 crore fund-raising through Qualified Institutional Placement (QIP).
The Board meeting scheduled for August 28, 2025, will consider the fundraising proposal and enabling resolutions.
The proposed research facility aims to research, validate, and scale processes for converting agricultural/botanical inputs into pharma-grade products for public health and societal wellbeing. The laboratory will comply with cGMP standards and the US FDA's Botanical Drug Development guidance, enabling participation in international markets for botanical/ayurvedic products with investment spanning infrastructure, pilot lines, and analytics systems.
| Market Segment | Current Value | Projected Value | Growth Rate
|
|---|---|---|---|
| Herbal/Botanical Medicine | $70.6 billion (2023) | $328.7 billion (2030) | ~21% CAGR |
| Botanical Supplements | $38.2 billion (2024) | - | 9.9% CAGR to 2030 |
| Indian Ayurvedic Products | ₹876 billion (2024) | - | 16% CAGR to 2033 |
The company proposes raising up to ₹80 crore through QIP in one or more tranches, complying with SEBI (ICDR) Regulations 2018 and other applicable laws. The August 28, 2025, Board meeting will consider fundraising approval, enabling resolutions, issue structure, and seeking shareholders' approval as required. Proceeds will fund the research laboratory and general corporate purposes.
Read More: Alembic Pharma Gets USFDA Nod for Generic Acne Drug Tretinoin Cream!
The proposal includes no related-party transactions and remains subject to Board, shareholder, regulatory, and statutory approvals alongside market conditions. The trading window closed as per SEBI Insider Trading Regulations will reopen 48 hours after the Board meeting outcome dissemination. Director Chintan Didawala Ganpat (DIN: 11088268) authorised the regulatory filing on August 20, 2025.
WHO notes strong policy adoption of traditional and complementary medicine globally, supporting Welcure's strategic expansion into agro-pharma research. The facility's alignment with US FDA botanical drug development guidance and cGMP standards positions the company to capitalise on international market opportunities whilst contributing to public health through validated botanical products.
On August 20, 2025, Welcure Drugs & Pharmaceuticals share price opened at ₹12.70 on BSE, above the previous close of ₹12.10. During the day, it surged to ₹12.70 and dipped to ₹12.69. The stock is trading at ₹12.70 as of 11:09 AM. The stock hit an upper circuit of 5%.
Over the past week, it has moved up by 11.99%, over the past month, it has moved up by 27.13%, and over the past 3 months, it has moved up by 12.69%.
Welcure Drugs & Pharmaceuticals' ₹70-80 crore Agro-Pharma Research Laboratory proposal with ₹80 crore QIP fund-raising represents strategic positioning in the rapidly growing botanical medicine market.
Disclaimer: This blog has been written exclusively for educational purposes. The securities or companies mentioned are only examples and not recommendations. This does not constitute a personal recommendation or investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.
Investments in securities are subject to market risks. Read all related documents carefully before investing.
Published on: Aug 20, 2025, 2:04 PM IST
Team Angel One
We're Live on WhatsApp! Join our channel for market insights & updates
Get the link to download the App
